229 related articles for article (PubMed ID: 36680181)
1. Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas.
Tsakogiannis D; Nikolaidis M; Zagouri F; Zografos E; Kottaridi C; Kyriakopoulou Z; Tzioga L; Markoulatos P; Amoutzias GD; Bletsa G
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680181
[TBL] [Abstract][Full Text] [Related]
2. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
3. HPV16 L1 diversity and its potential impact on the vaccination-induced immunity.
El Aliani A; El Abid H; Kassal Y; Khyatti M; Attaleb M; Ennaji MM; El Mzibri M
Gene; 2020 Jul; 747():144682. PubMed ID: 32304786
[TBL] [Abstract][Full Text] [Related]
4. Characterization of major capsid protein (L1) variants of Human papillomavirus type 16 by cervical neoplastic status in Indian women: Phylogenetic and functional analysis.
Mane A; Patil L; Limaye S; Nirmalkar A; Kulkarni-Kale U
J Med Virol; 2020 Aug; 92(8):1303-1308. PubMed ID: 31944308
[TBL] [Abstract][Full Text] [Related]
5. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
6. Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women.
Mane A; Limaye S; Patil L; Kulkarni-Kale U
Med Microbiol Immunol; 2022 Jun; 211(2-3):153-160. PubMed ID: 35552511
[TBL] [Abstract][Full Text] [Related]
7. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
8. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
9. Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16.
Chen J; Wang D; Wang Z; Wu K; Wei S; Chi X; Qian C; Xu Y; Zhou L; Li Y; Zhang S; Li T; Kong Z; Wang Y; Zheng Q; Yu H; Zhao Q; Zhang J; Xia N; Li S; Gu Y
J Virol; 2023 Mar; 97(3):e0181922. PubMed ID: 36815785
[TBL] [Abstract][Full Text] [Related]
10. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
11. HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer.
Namvar A; Bolhassani A; Hashemi M
Bratisl Lek Listy; 2016; 117(3):179-84. PubMed ID: 26925750
[TBL] [Abstract][Full Text] [Related]
12. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
14. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
15. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.
Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S
Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682
[TBL] [Abstract][Full Text] [Related]
16. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
19. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
20. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
